The Centers for Medicare and Medicaid Services should reopen its Medicare national coverage determination for Eli Lilly and Company’s Alzheimer’s drug donanemab based on the company’s clinical trial and real-world data, Lilly researchers conclude in a paper published in the journal Alzheimer’s & Dementia earlier this month.
Key Takeaways
-
Lilly is marshalling its data to demonstrate that patient registry requirements should not be a condition of Medicare coverage for donanemab.
Issued in April 2022, the Medicare NCD limits reimbursement of anti-amyloid monoclonal antibody treatments with traditional US Food and Drug...